Same active ingredient. Different doses, approvals, and insurance coverage. Here's everything you need to know to understand which is right for you.
Ozempic and Wegovy are the same drug — both contain semaglutide, made by Novo Nordisk. The difference is the FDA approval and maximum dose. Ozempic (max 2mg) is approved for type 2 diabetes. Wegovy (max 2.4mg) is approved for obesity and weight loss. That single difference has enormous implications for who gets prescribed which, how insurance covers each, and how much you pay.
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA Approval | Type 2 Diabetes | Obesity / Weight Loss |
| Approved Year | 2017 | 2021 |
| Starting Dose | 0.25 mg/week | 0.25 mg/week |
| Maximum Dose | 2.0 mg/week | 2.4 mg/week |
| Titration Steps | 4 steps (0.25→0.5→1→2mg) | 5 steps (0.25→0.5→1→1.7→2.4mg) |
| Avg Weight Loss | ~13–15% | ~15% (slightly more at 2.4mg) |
| Heart Disease Benefit | ✅ SUSTAIN-6 (20yr high-risk) | ✅ SELECT trial (20% reduction) |
| List Price / Month | ~$935 | ~$1,349 |
| Insulin/Diabetes Coverage | ✅ Usually covered | N/A (not diabetes drug) |
| Obesity Insurance Coverage | ❌ Not approved for obesity | ✅ Improving — now Medicare covers |
| Pen Type | Reusable multi-dose pen | Single-use autoinjector |
| Pen Colors | Blue (0.5mg), Red (1mg), Teal (2mg) | Distinct pen per dose level |
| Manufacturer Savings | $0–99/mo (commercially insured) | $0–199/mo (commercially insured) |
| Compounded Version | No (off shortage list) | No (off shortage list) |
| Best For | Type 2 diabetics, insured patients | Obesity without diabetes, weight loss focus |
This is the most important difference. Ozempic is FDA-approved to treat type 2 diabetes. Wegovy is FDA-approved to treat obesity and overweight with related health conditions. Same molecule, entirely different regulatory pathways.
Why it matters: If you have type 2 diabetes, your doctor will likely prescribe Ozempic and your insurance will cover it. If you want to lose weight without diabetes, Wegovy is the correct drug — but insurance may or may not cover it depending on your plan.
Wegovy's maximum dose (2.4mg) is 20% higher than Ozempic's (2.0mg). That extra 0.4mg is why Wegovy was specifically designed for weight loss — higher semaglutide doses produce greater appetite suppression.
In practice, clinical trials show Wegovy at 2.4mg produces slightly more weight loss than Ozempic at 2.0mg, though the difference isn't dramatic. Many patients do well at 1mg or less and never reach either maximum dose.
Wegovy costs about $414 more per month at list price. However, what you actually pay depends almost entirely on your insurance:
Ozempic uses a reusable multi-dose pen — you attach a new needle for each injection but use the same pen until the medication runs out. Wegovy uses a single-use autoinjector — one pen per injection, simpler for many patients. Wegovy's autoinjector hides the needle, which some needle-phobic patients prefer.
Insurance coverage is where Ozempic vs Wegovy gets complicated. Here's the honest breakdown:
| Insurance Type | Ozempic | Wegovy |
|---|---|---|
| Commercial (employer) — diabetes | ✅ Usually covered | Not applicable |
| Commercial (employer) — obesity | Not approved for this | ⚠️ ~50% of plans now cover |
| Medicare Part D | ✅ Covered for diabetes | ✅ Now covered (2026) |
| Medicaid | ✅ Most states | ⚠️ Varies by state |
| No insurance | $935/mo list | $1,349/mo list |
| Manufacturer savings card | $0–$99/mo | $0–$199/mo |
Coverage details change frequently. Always verify with your insurance company. Prior authorization is typically required for both drugs.
Yes — patients switch between these drugs regularly, especially when moving from diabetes management to a weight loss focus, or when insurance coverage changes. The transition is straightforward since they're the same molecule. Your doctor will determine the appropriate dose to start Wegovy based on your current Ozempic dose.
At maximum dose, yes — Wegovy's 2.4mg is higher than Ozempic's 2.0mg. However, "stronger" depends on the dose you actually reach. Many patients stabilize well below the maximum for both drugs. The extra 0.4mg in Wegovy is meaningful for weight loss but won't make a dramatic difference for most people who plateau at lower doses.
Novo Nordisk priced them differently because they serve different markets. Ozempic competes with other diabetes drugs where insurance negotiation is more established. Wegovy targets the obesity market where payers are less experienced, and the company charged a premium for the weight-loss-specific approval and higher dose.
Yes — off-label prescribing is legal and common. Many doctors prescribe Ozempic off-label for weight loss in patients without diabetes, especially when insurance won't cover Wegovy. However, insurance typically won't cover Ozempic for weight loss either — so the cost difference becomes less relevant if you're paying out of pocket.
Both contain semaglutide, but Wegovy is FDA-approved for weight loss at a higher dose (2.4mg), while Ozempic is approved for Type 2 diabetes at lower doses (up to 2mg).
Wegovy produces slightly more weight loss (average ~15%) due to its higher dose vs Ozempic (~10-15%). Wegovy is specifically designed for obesity treatment.
Yes, doctors often prescribe Ozempic off-label for weight loss, but insurance coverage for this use is inconsistent. Wegovy is the FDA-approved option for obesity.